Cipher Pharmaceuticals Inc.

Cipher reported Q2 2026 net revenue of $12.1 million and six-month revenue of $24.6 million. Net revenue fell 10% year over year in the quarter and 3% year over year year to date, primarily because of lower Natroba revenue, partially offset by Epuris growth and reduced shipment/licensing revenue variability. Gross margin was 80% in Q2 2026, down from 81% a year ago, and 81% year to date versus 79% in the prior year period. Net income was $4.0 million, or $0.15 per diluted share, versus $5.9 million, or $0.22, last year; year-to-date net income was $10.2 million, or $0.39, versus $8.5 million, or $0.32. Adjusted EBITDA was $6.8 million in Q2 2026 versus $7.6 million last year, and $14.6 million year to date versus $13.8 million. Management did not give formal next-quarter or full-year financial guidance; instead, it said Natroba performance is expected to improve in future quarters as new commercial programs take effect, and Epuris should benefit from expanded public reimbursement coverage once listings are finalized over the next 30 to 60 days.

Craig Mull described Cipher as a highly profitable specialty pharma platform with strong cash flows, emphasizing that the company’s core businesses remain robust despite pressure on U.S. Natroba volumes. He highlighted growth in Canada, especially Epuris, and framed the pCPA letter of intent as an important step that should expand patient access and market share over time. His tone was constructive and opportunistic, with repeated emphasis on business development, including in-licensing, out-licensing, and acquisitions to add scale.

Ryan Mailling focused on the financial resilience of the business, noting gross margin of 80% in Q2 and 81% year to date, along with adjusted EBITDA of $6.8 million in the quarter and $14.6 million year to date. He said SG&A fell to $3.4 million from $4.1 million in Q2, helped by lower non-recurring legal costs, operational efficiencies, and reduced selling and marketing expense; year-to-date SG&A declined to $6.3 million from $9.0 million. He also said Cipher ended the quarter with $9.1 million in cash, generated $7.6 million of operating cash flow in the first half, remained debt-free, and had $90 million of potential financing capacity consisting of a $65 million revolver plus a $25 million accordion.

Analysts focused on three areas: the Medicaid-driven pressure on Natroba, the company’s abandoned acquisition process, and the quarter’s weaker free cash flow. Management said it could not discuss Medicaid policy specifics, but explained that changing covered lives and rebate timing affect results; it is responding by expanding direct-to-patient access, same-day or mail delivery, and retail placement, including availability at Walmart. On the deal it stepped away from, Craig Mull said it was a larger target that fit the model, but concerns about some products and price made it the wrong transaction at this time. Ryan Mailling also said the working-capital pressure tied to contract liabilities reflected payer rebates and the timing of cash receipts versus future rebate payments.